Three Gene Signature for Predicting the Development of Hepatocellular Carcinoma in Chronically Infected Hepatitis C Virus Patients
Publication: Journal of Interferon & Cytokine Research
Volume 36, Issue Number 12
Abstract
Hepatitis C virus (HCV) is the leading cause of liver fibrosis and hepatocellular carcinoma (HCC). At present, there is no predictive biomarker for the patients at high risk of developing HCC. In this study, we examined the association between single-nucleotide polymorphisms (SNPs) in 3 innate immunity genes [2′-5′oligoadenylate synthetase 1 (OAS1) rs10774671, interleukin 28B (IL28B) rs12979860, and low molecular mass polypeptide 7 (LMP-7) at codon 49] besides cytomegalovirus (CMV) coinfection and susceptibility to HCC in genotype 4 (GT4) chronically infected Egyptian patients. SNPs were determined using restriction fragment length polymorphism analysis in DNA from HCC patients (n = 34) and compared with either controls (n = 70) or patients with early grades of liver fibrosis (n = 49). Our results demonstrated that patients bearing the genetic combination consisting of LMP-7 CA/AA [OR 4.75, 95% confidence interval (CI) 1.443–15.631, P = 0.007] and IL28B rs12979860 CT/TT (OR 6.00, 95% CI 1.603–22.455, P = 0.004) and positive for CMV viremia (OR 3.11, 95% CI 1.151–8.412, P = 0.02) were more likely to have HCC. However, OAS1 rs10774671 does not seem to contribute to the development of HCC. Binary regression analysis indicated that HCC risk significantly increases with the presence of each unfavorable genotype (LMP-7 CA/AA, IL28B rs12979860 CT/TT), when accompanied by the existence of CMV coinfection (probability of HCC risk is 0.8 for combined factors versus 0.14, 0.07, and 0.07 for individual factor IL28B, LMP-7, and CMV; respectively). These data suggest that the 2 SNPs and the coinfection in concert have potential in predicting the risk of HCC development in patients infected with HCV GT4.
Get full access to this article
View all available purchase options and get full access to this article.
References
Akkiz H, Kuran S, Akgollu E, Uskudar O, Bekar A, Bayram S. 2014. The role of interleukin 28B gene polymorphism in Turkish patients with hepatocellular carcinoma. Ann Hepatol 13(6):788–795.
Andrade L, Melo R, Souza E, Silva C, Parana R. 2009. Association between hepatitis C and hepatocellular carcinoma. J Glob Infect Dis 1(1):5.
Bader el-Din NG, Abd el-Meguid M, Tabll AA, Anany MA, Esmat G, Zayed N, Helmy A, el-Zayady AR, Barakat A, el-Awady MK. 2011. Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy. J Gastroenterol Hepatol 26(1):55–62.
Bader El Din NG, Anany MA, Dawood RM, Ibrahim MK, El-Shenawy R, El Abd YS, El Awady MK. 2015. Impact of OAS1 exon 7 rs10774671 genetic variation on liver fibrosis progression in Egyptian HCV genotype 4 patients. Viral Immunol 28(9):509–516.
Bayram A, Ozkur A, Erkilic S. 2009. Prevalence of human cytomegalovirus co-infection in patients with chronic viral hepatitis B and C: a comparison of clinical and histological aspects. J Clin Virol 45(3):212–217.
Cao B, Tian X, Li Y, Jiang P, Ning T, Xing H, Zhao Y, Zhang C, Shi X, Chen D, Shen Y, Ke Y. 2005. LMP7/TAP2 gene polymorphisms and HPV infection in esophageal carcinoma patients from a high incidence area in China. Carcinogenesis 26(7):1280–1284.
Chang KC, Tseng PL, Wu YY, Hung HC, Huang CM, Lu SN, Wang JH, Lee CM, Chen CH, Tsai MC, Yen YH, Lin MT, Wu CK, Huang CC, Chen HH, Hu TH. 2015. A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection. Clin Gastroenterol Hepatol 13(5):1017–1024.
Chopra KB, Demetris AJ, Blakolmer K, Dvorchik I, Laskus T, Wang LF, Araya VR, Dodson F, Fung JJ, Rakela J, Vargas HE. 2003. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. Transplantation 76(10):1487–1491.
Cui Q, Zhang Y, Su J, Shi C, Lei N, Ding K, Li J, Yu R, Wang L, Wang N. 2010. The association between the genetic polymorphisms of LMP2/LMP7 and the outcomes of HCV infection among drug users. J Biomed Res 24(5):374–380.
de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, Silverman RH, Williams BR. 2001. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 69(6):912–920.
El-Awady MK, Mostafa L, Tabll AA, Abdelhafez TH, Bader El Din NG, Zayed N, Shenawy RE, El Abd Y, Hasan RM, Zaghlol H, El Khayat H, Abdel Aziz AO. 2012. Association of IL28B SNP with progression of Egyptian HCV genotype 4 patients to end stage liver disease. Hepat Mon 12(4):271–277.
El Awady MK, Anany MA, Esmat G, Zayed N, Tabll AA, Helmy A, El Zayady AR, Abdalla MS, Sharada HM, El Raziky M, El Akel W, Abdalla S, Bader El Din NG. 2011. Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy. J Gastroenterol Hepatol 26(5):843–850.
Fellerhoff B, Gu S, Laumbacher B, Nerlich AG, Weiss EH, Glas J, Kopp R, Johnson JP, Wank R. 2011. The LMP7-K allele of the immunoproteasome exhibits reduced transcript stability and predicts high risk of colon cancer. Cancer Res 71(23):7145–7154.
Fox JD, Brink NS, Zuckerman MA, Neild P, Gazzard BG, Tedder RS, Miller RF. 1995. Detection of herpesvirus DNA by nested polymerase chain reaction in cerebrospinal fluid of human immunodeficiency virus-infected persons with neurologic disease: a prospective evaluation. J Infect Dis 172(4):1087–1090.
French BA, Oliva J, Bardag-Gorce F, French SW. 2011. The immunoproteasome in steatohepatitis: its role in Mallory-Denk body formation. Exp Mol Pathol 90(3):252–256.
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262):399–401.
Gobel T, Vorderwulbecke S, Hauck K, Fey H, Haussinger D, Erhardt A. 2006. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. World J Gastroenterol 12(47):7604–7612.
Goossens N, Hoshida Y. 2015. Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol 21(2):105–114.
Imran M, Manzoor S, Khattak NM, Tariq M, Khalid M, Javed F, Bhatti S. 2014. Correlation of OAS1 gene polymorphism at exon 7 splice accepter site with interferon-based therapy of HCV infection in Pakistan. Viral Immunol 27(3):105–111.
Ishida C, Ikebuchi Y, Okamoto K, Murawaki Y. 2011. Functional gene polymorphisms of interleukin-10 are associated with liver disease progression in Japanese patients with hepatitis C virus infection. Intern Med 50(7):659–666.
Jones RN, Neale ML, Beattie B, Westmoreland D, Fox JD. 2000. Development and application of a PCR-based method including an internal control for diagnosis of congenital cytomegalovirus infection. J Clin Microbiol 38(1):1–6.
Koziel MJ. 1999. Cytokines in viral hepatitis. Semin Liver Dis 19(2):157–169.
Li T, Fan J, Qin LX, Zhou J, Sun HC, Qiu SJ, Ye QH, Wang L, Tang ZY. 2011. Risk factors, prognosis, and management of early and late intrahepatic recurrence after resection of primary clear cell carcinoma of the liver. Ann Surg Oncol 18(7):1955–1963.
Liu L, Yan M, Zhang XH, Zhu P, Zhang L. 2008. [An experimental study on the relationship between proteasome LMP7 subunit and alcoholic liver disease]. Zhonghua Gan Zang Bing Za Zhi 16(11):827–830.
Ma J, Liu YC, Fang Y, Cao Y, Liu ZL. 2015. TGF-beta1 polymorphism 509 C>T is associated with an increased risk for hepatocellular carcinoma in HCV-infected patients. Genet Mol Res 14(2):4461–4468.
McCaughan GW, George J. 2004. Fibrosis progression in chronic hepatitis C virus infection. Gut 53(3):318–321.
Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. 2013. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57(4):1333–1342.
Omran MH, Fotouh BE, Youssef SS, Ibrahim NE, Nabil W, Mahdy el SM, Shosha WG, El-Awady MK. 2013. Association between low molecular polypeptide 7 single nucleotide polymorphism and response to therapy in hepatitis C virus infection. World J Hepatol 5(3):97–103.
Par A, Par G, Tornai I, Szalay F, Varszegi D, Frater E, Papp M, Lengyel G, Feher J, Varga M, Gervain J, Schuller J, Nemes Z, Peterfi Z, Tusnadi A, Hunyady B, Haragh A, Szinku Z, Vincze A, Szereday L, Kisfali P, Melegh B. 2014. IL28B and IL10R −1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort. BMC Res Notes 7:12.
Park JS, Neeraj S, Dieterich DT. 2005. Antiviral therapy in the HCV-coinfected patient with HIV and/or HBV. Curr Hepat Rep 4(2):4.
Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Gunthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Mullhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY. 2010a. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138(4):1338–1345, 1345 e1–e7.
Rauch A, Rohrbach J, Bochud PY. 2010b. The recent breakthroughs in the understanding of host genomics in hepatitis C. Eur J Clin Invest 40(10):950–959.
Razonable RR, Burak KW, van Cruijsen H, Brown RA, Charlton MR, Smith TF, Espy MJ, Kremers W, Wilson JA, Groettum C, Wiesner R, Paya CV. 2002. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis 35(8):974–981.
Rosen HR, Chou S, Corless CL, Gretch DR, Flora KD, Boudousquie A, Orloff SL, Rabkin JM, Benner KG. 1997. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 64(5):721–726.
Sebastiani G, Alberti A. 2006. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 12(23):3682–3694.
Song L, Ma N, Han L, Yan H, Yan B, Yuan Z, Cao B. 2014. Association between LMP2/LMP7 genetic variability and the metastasis risk of ovarian cancer in Chinese women in Beijing. Hum Immunol 75(3):239–244.
Stark GR. 2007. How cells respond to interferons revisited: from early history to current complexity. Cytokine Growth Factor Rev 18(5–6):419–423.
Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41(10):1105–1109.
Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. 2009. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461(7265):798–801.
Thompson A, Patel K, Tillman H, McHutchison JG. 2009. Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. J Hepatol 50(1):184–194.
Tolmane I, Rozentale B, Keiss J, Ivancenko L, Subnikova N, Reinholde Z, Kozlovska I, Sumlaninova N, Laivacuma S, Simanis R. 2012. Interleukin 28B gene polymorphism and association with chronic hepatitis C therapy results in Latvia. Hepat Res Treat 2012:324090.
Trowsdale J, Hanson I, Mockridge I, Beck S, Townsend A, Kelly A. 1990. Sequences encoded in the class II region of the MHC related to the ‘ABC’ superfamily of transporters. Nature 348(6303):741–744.
Vargas-Alarcon G, Gamboa R, Zuniga J, Fragoso JM, Hernandez-Pacheco G, Londono J, Pacheco-Tena C, Cardiel MH, Granados J, Burgos-Vargas R. 2004. Association study of LMP gene polymorphisms in Mexican patients with spondyloarthritis. Hum Immunol 65(12):1437–1442.
WHO. 2014. Hepatitis C, WHO fact sheet No. 164, updated April. Available at www.who.int/mediacentre/factsheets/fs164/en
York IA, Rock KL. 1996. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 14:369–396.
Zekri AR, Salama H, Medhat E, Bahnassy AA, Morsy HM, Lotfy MM, Ahmed R, Darwish T, Marei MS. 2014. IL28B rs12979860 gene polymorphism in Egyptian patients with chronic liver disease infected with HCV. Asian Pac J Cancer Prev 15(17):7213–7218.
Information & Authors
Information
Published In
Journal of Interferon & Cytokine Research
Volume 36 • Issue Number 12 • December 2016
Pages: 698 - 705
PubMed: 27726464
Copyright
Copyright 2016, Mary Ann Liebert, Inc.
History
Published in print: December 2016
Published online: 1 December 2016
Published ahead of print: 11 October 2016
Accepted: 3 August 2016
Received: 30 April 2016
Topics
- Biomedical science, research and development
- Diagnostic techniques
- DNA and cell biology
- Gastrointestinal cancer
- Gene polymorphism
- Genetic techniques
- Hepatitis
- Hepatitis virus
- Hepatocellular carcinoma
- Infectious diseases
- Liver cancer
- Medicine, Surgery & Diagnosis
- Neoplasm
- Pathogens
- Polymerase chain reaction
- Viral diseases
- Viruses
Authors
Author Disclosure Statement
No competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.